Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Abstract

Renal-cell carcinoma (RCC) remains a leading cause of cancer-related mortality worldwide. Though newer therapeutic combinations of immune checkpoint inhibitors and targeted therapies have greatly improved outcomes, resistance to these therapies is becoming a challenge for long-term control. Mechanisms of resistance have been explored in a variety of solid tumors, including RCC. Based upon our review of the current literature on the mechanisms of resistance to immunotherapies for the management of metastatic clear-cell renal cell carcinomas (mccRCC), the ensuing conclusions have been made:

The management of mccRCC has progressed substantially with the advent of checkpoint inhibitors and targeted oral therapies, alone and/or in combination.

Nevertheless, innate or developed resistance to these therapies remains an ongoing challenge, particularly to immune checkpoint inhibitors (ICIs).

Several of the known mechanisms of resistance have been well defined, but recent progression in cellular therapies helps to expand the armamentarium of potential combination options that may overcome these modes of resistance and improve long-term disease control and survival for an otherwise dismal disease.

In the ensuing review and update of the literature on the mechanisms of resistance to immunotherapies in mccRCC, we have revisited the known resistance mechanisms of immunotherapies in metastatic clear-cell RCC and explored ongoing and future strategies to overcome them.

Keywords

Metastatic clear-cell renal-cell carcinoma / immune therapy / checkpoint inhibitor resistance / chimeric antigen receptor T-cell therapy

References

[1] SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. Available from: https://seer.cancer.gov/statistics-network/explorer/. [Last accessed on 2 Jun 2023]

[2] Lopez-Beltran A,Montironi R.2004 WHO classification of the renal tumors of the adults.Eur Urol2006;49:798-805

[3] Finke JH,Hart L.Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.J Immunother Emphasis Tumor Immunol1994;15:91-104

[4] Giraldo NA,Pagès F.Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer.Clin Cancer Res2015;21:3031-40

[5] Jian Y,Sun X.Current advance of immune evasion mechanisms and emerging immunotherapies in renal cell carcinoma.Front Immunol2021;12:639636 PMCID:PMC7985340

[6] Gnarra JR,Weng Y.Mutations of the VHL tumour suppressor gene in renal carcinoma.Nat Genet1994;7:85-90

[7] Motzer RJ,Tomczak P.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med2007;356:115-24

[8] Casper J,Köhne CH.Pazopanib versus sunitinib in renal cancer.N Engl J Med2013;369:1968-70

[9] Escudier B,Stadler WM et al.Sorafenib in advanced clear-cell renal-cell carcinoma.NEJM2007;356:125-34

[10] Wu Z,Qu L.Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis.Eur Urol2022;81:414-25

[11] Makhov P,Ghatalia P,Uzzo RG.Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies.Mol Cancer Ther2018;17:1355-64 PMCID:PMC6034114

[12] Moreira M,Epaillard N,Oudard S.Resistance to cancer immunotherapy in metastatic renal cell carcinoma.Cancer Drug Resist2020;3:454-71 PMCID:PMC8992500

[13] Motzer RJ,Bacik J,Amsterdam A.Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.J Clin Oncol1999;17:2530-40

[14] Heng DY,Regan MM.Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol2009;27:5794-9

[15] Powles T,Soulières D et al.Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.Lancet Oncol2020;21:1563-73.

[16] Motzer RJ,Burotto M et al.Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.Lancet Oncol2022;23:888-98

[17] Motzer R,Rha SY.CLEAR Trial InvestigatorsLenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.N Engl J Med2021;384:1289-300

[18] Motzer RJ,Agarwal N.Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2022;20:71-90 PMCID:PMC10191161

[19] Motzer RJ,Oudard S.RECORD‐1 Study GroupPhase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.Cancer2010;116:4256-65

[20] Hudes G,Tomczak P.Global ARCC TrialTemsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med2007;356:2271-81

[21] Choueiri TK,Park SH.KEYNOTE-564 InvestigatorsAdjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.N Engl J Med2021;385:683-94

[22] Powles T,Park SH et al.Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2022;23:1133-44.

[23] Blank CU,Ribas A.The cancer immunogram.Science2016;352:658-60

[24] Fares CM,Drake CG,Hu-Lieskovan S.Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?.Am Soc Clin Oncol Educ Book2019;39:147-64

[25] Wallis CJD,Satkunasivam R.Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis.JAMA Oncol2019;5:529-36 PMCID:PMC6459215

[26] Jang SR,Banks J.Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma.JAMA Netw Open2021;4:e2136823 PMCID:PMC8640892

[27] Scott SC,Niknafs N.Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.Front Oncol2022;12:945798 PMCID:PMC9382103

[28] Derosa L,Fidelle M.Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients.Eur Urol2020;78:195-206

[29] Sivan A,Hubert N.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science2015;350:1084-9 PMCID:PMC4873287

[30] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[31] Dizman N,Bergerot P.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.Nat Med2022;28:704-12 PMCID:PMC9018425

[32] Ueda K,Ogasawara N.The impact of antibiotics on prognosis of metastatic renal cell carcinoma in japanese patients treated with immune checkpoint inhibitors.Anticancer Res2019;39:6265-71

[33] Luo Z,Li Y.The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.Front Immunol2022;13:1065004 PMCID:PMC9727164

[34] Eng L,Niu Y.Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study.J Clin Oncol2023;:JCO2200074

[35] Petrelli F,Ghidini M.Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Cancers2020;12:546 PMCID:PMC7139305

[36] Dutcher JP,Fallah J.On the shoulders of giants: the evolution of renal cell carcinoma treatment-cytokines, targeted therapy, and immunotherapy.Am Soc Clin Oncol Educ Book2020;40:1-18

[37] Barrueto L,Cash L,Lamichhane P.Resistance to checkpoint inhibition in cancer immunotherapy.Transl Oncol2020;13:100738 PMCID:PMC7047187

[38] Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells.Nat Rev Cancer2023;23:193-215

[39] Masini C,De Giorgi U.Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. results of the phase II NIVES study.Eur Urol2022;81:274-82

[40] Hammers HJ,Ahn C.Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).JCO2020;38:614-614

[41] Seung SK,Crittenden M et al.Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.Sci Transl Med2012;4:137ra74-ra74

[42] Curti B,Seung SK.Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.J Immunother Cancer2020;8:e000773 PMCID:PMC7259841

[43] Chow A,Klebanoff CA.Clinical implications of T cell exhaustion for cancer immunotherapy.Nat Rev Clin Oncol2022;19:775-90

[44] Thommen DS.T cell dysfunction in cancer.Cancer Cell2018;33:547-62 PMCID:PMC7116508

[45] Wherry EJ,Kaech SM.Molecular signature of CD8+ T cell exhaustion during chronic viral infection.Immunity2007;27:670-84

[46] Thompson RH,Lohse CM.PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.Clin Cancer Res2007;13:1757-61

[47] Kang MJ,Bae JS.Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma.Transl Oncol2013;6:282-9 PMCID:PMC3660796

[48] Jiang Y,Zhu B.T-cell exhaustion in the tumor microenvironment.Cell Death Dis2015;6:e1792 PMCID:PMC4669840

[49] Giraldo NA,Vano Y.Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma.Clin Cancer Res2017;23:4416-28

[50] Fridman WH,Sautès-Fridman C.The immune contexture in human tumours: impact on clinical outcome.Nat Rev Cancer2012;12:298-306

[51] Gooden MJ,Leffers N,Nijman HW.The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.Br J Cancer2011;105:93-103 PMCID:PMC3137407

[52] Nakano O,Naito Y et al.Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.Cancer Res2001;61:5132-6

[53] Braun DA,Hirsch L.Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.Nat Rev Clin Oncol2021;18:199-214 PMCID:PMC8317018

[54] Verma NK,Poh ZS.Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint.EBioMedicine2022;83:104216 PMCID:PMC9403334

[55] Alkhouli MA,Pilon-Thomas S,Chahoud J.Current state of cell therapies for genitourinary malignancies.Cancer J2022;28:294-300

[56] Granier C,Combe P.Tim-3 expression on tumor-infiltrating PD-1⁺CD8⁺ T cells correlates with poor clinical outcome in renal cell carcinoma.Cancer Res2017;77:1075-82

[57] Castillo-Rodríguez RA,Cabrera-Cano A,Dávila-Borja VM.Hypoxia as a modulator of inflammation and immune response in cancer.Cancers2022;14:2291 PMCID:PMC9099524

[58] Pietrobon V.Hypoxia and the phenomenon of immune exclusion.J Transl Med2021;19:9 PMCID:PMC7788724

[59] Choueiri TK,Papadopoulos KP.Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Nat Med2021;27:802-5 PMCID:PMC9128828

[60] FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease. [Last accessed on 30 May 2023]

[61] Ballesteros PÁ,Román-Gil MS.Molecular mechanisms of resistance to immunotherapy and antiangiogenic treatments in clear cell renal cell carcinoma.Cancers2021;13:5981 PMCID:PMC8656474

[62] Carretero-González A,Martín Sobrino I.The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials.Cancers2020;12:1945 PMCID:PMC7409133

[63] Zhu J,Friedlander TW.Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.J Immunother Cancer2018;6:4 PMCID:PMC5784676

[64] Choueiri TK,Haanen JBAG.Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).JCO2019;37:101-101

[65] Geertsen L,Thomassen M,Lund L.Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature.Eur Urol Open Sci2022;37:27-35 PMCID:PMC8784339

[66] Kim YJ,Kim JS.Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.Sci Rep2021;11:5600 PMCID:PMC7970914

[67] Hahn AW,Maughan BL.Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses.KCA2019;3:7-13

[68] Goodman AM,Bazhenova L.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther2017;16:2598-608 PMCID:PMC5670009

[69] di Meo NA,Rutigliano M.Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets.Int J Mol Sci2022;23:14360 PMCID:PMC9698586

[70] Mock A,Kirsten R.Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.Cancer Immunol Immunother2019;68:2005-14

[71] Hoefflin R,Schäfer S.HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.Nat Commun2020;11:4111 PMCID:PMC7431415

[72] Wang G,Jian WG.Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway.Mol Cancer2019;18:15 PMCID:PMC6341572

[73] Medical Research Council Renal Cancer CollaboratorsInterferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial.Lancet1999;353:14-7

[74] Fyfe G,Rosenberg SA,Parkinson DR.Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.J Clin Oncol1995;13:688-96

[75] Parton M,Eisen T.Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.J Clin Oncol2006;24:5584-92

[76] Buchbinder EI,Daniels GA.Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.J Immunother Cancer2019;7:49 PMCID:PMC6380045

[77] Tannir NM,Diab A.Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.J Immunother Cancer2022;10:e004419 PMCID:PMC9021810

[78] Tannir NM,Pal SK.PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma (RCC).JCO2020;38:TPS763-TPS763

[79] Clinicaltrials.gov. A study of bempegaldesleukin (NKTR-214: BEMPEG) in combination with nivolumab compared with the investigator's choice of a Tyrosine Kinase Inhibitor (TKI) therapy (either sunitinib or cabozantinib monotherapy) for advanced metastatic renal cell carcinoma (RCC). Available from: https://clinicaltrials.gov/ct2/show/NCT03729245. [Last accessed on 30 May 2023]

[80] Chatzkel J,Chahoud J.Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer.Clin Genitourin Cancer2022;20:252-9

[81] June CH.Chimeric antigen receptor therapy.N Engl J Med2018;379:64-73 PMCID:PMC7433347

[82] Neelapu SS,Bartlett NL.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[83] FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma. [Last accessed on 30 May 2023]

[84] Locke FL,Jacobson CA.All ZUMA-7 investigators and contributing kite membersAxicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.N Engl J Med2022;386:640-54

[85] Maude SL,Buechner J.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med2018;378:439-48 PMCID:PMC5996391

[86] Shah BD,Oluwole OO.KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.Lancet2021;398:491-502

[87] Schuster SJ,Tam CS.JULIET InvestigatorsTisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma.N Engl J Med2019;380:45-56

[88] Jacobson CA,Sehgal AR.Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Lancet Oncol2022;23:91-103

[89] Abramson JS,Gordon LI.Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020;396:839-52

[90] Munshi NC,Shah N.Idecabtagene vicleucel in relapsed and refractory multiple myeloma.N Engl J Med2021;384:705-16

[91] Sterner RC.CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021;11:69 PMCID:PMC8024391

[92] Ye H,Shuch BM.CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.JCO2022;40:384-384

[93] Panowski SH,Tan N.Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma.Cancer Res2022;82:2610-24

[94] Wang QJ,Hanada KI.Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers.Clin Cancer Res2017;23:2267-76 PMCID:PMC5411349

[95] Pal SK,Hannen JB. CTX130 allogeneic CRISPR-Cas9 - engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: results from the phase 1 COBALT-RCC study. Presented at: 2022 SITC Annual Meeting; November 8-12, 2022; Boston, MA. Available from: http://ir.crisprtx.com/static-files/0941e694-f38e-41d3-b13d-1f7e15523054. [Last accessed on 30 May 2023]

[96] Lamers CH,Gratama JW,Debets R.Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.Biochem Soc Trans2016;44:951-9

[97] Li H,Lu M.CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models.J Immunother2020;43:16-28

[98] Markel G,Besser MJ et al.Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.Anticancer Res2009;29:145-54. PMID: 19331144

[99] Andersen R,Westergaard MC,Hansen M.Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Hum Vaccin Immunother2015;11:2790-5 PMCID:PMC5054777

[100] Andersen R,Kjeldsen JW.T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy.Cancer Immunol Res2018;6:222-35

[101] Figlin RA,Kaboo R.Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.J Urol1997;158:740-5

[102] Yin H,Sun X,Feng C.TILs and anti-PD1 therapy: an alternative combination therapy for PDL1 negative metastatic cervical cancer.J Immunol Res2020;2020:8345235 PMCID:PMC7492938

[103] Baldan V,Hawkins RE.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma.Br J Cancer2015;112:1510-8 PMCID:PMC4453687

[104] Zhu Z,Jiang W,Kalinski P.Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.Mol Cancer2022;21:196 PMCID:PMC9554963

[105] Chesney J,Collichio F.Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.J Clin Oncol2018;36:1658-67 PMCID:PMC6075852

[106] Han G,Cao Z.Abstract 4022: PT2385, a novel HIF-2α antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration.Cancer Research2016;76:4022-4022

[107] Chen D,Zhang X.Inhibition of the CDK4/6-Cyclin D-Rb Pathway by ribociclib augments chemotherapy and immunotherapy in renal cell carcinoma.Biomed Res Int2020;2020:9525207 PMCID:PMC7306082